|
|
|
|
Cancer-associated splicing variant of tumor suppressor AIMP2/p38: Pathological implication in tumorigenesis
|
|
|
|
|
|
|
|
نویسنده
|
choi j.w. ,kim d.g. ,lee a.-e. ,kim h.r. ,lee j.y. ,kwon n.h. ,shin y.k. ,hwang s.-k. ,chang s.-h. ,cho m.-h. ,choi y.-l. ,kim j. ,oh s.h. ,kim b. ,kim s.-y. ,jeon h.-s. ,park j.y. ,kang h.p. ,park b.j. ,han j.m. ,kim s.
|
|
منبع
|
plos genetics - 2011 - دوره : 7 - شماره : 3
|
|
چکیده
|
Although ars-interacting multifunctional protein 2 (aimp2,also named as msc p38) was first found as a component for a macromolecular trna synthetase complex,it was recently discovered to dissociate from the complex and work as a potent tumor suppressor. upon dna damage,aimp2 promotes apoptosis through the protective interaction with p53. however,it was not demonstrated whether aimp2 was indeed pathologically linked to human cancer. in this work,we found that a splicing variant of aimp2 lacking exon 2 (aimp2-dx2) is highly expressed by alternative splicing in human lung cancer cells and patient's tissues. aimp2-dx2 compromised pro-apoptotic activity of normal aimp2 through the competitive binding to p53. the cells with higher level of aimp2-dx2 showed higher propensity to form anchorage-independent colonies and increased resistance to cell death. mice constitutively expressing this variant showed increased susceptibility to carcinogen-induced lung tumorigenesis. the expression ratio of aimp2-dx2 to normal aimp2 was increased according to lung cancer stage and showed a positive correlation with the survival of patients. thus,this work identified an oncogenic splicing variant of a tumor suppressor,aimp2/p38,and suggests its potential for anti-cancer target. © 2011 choi et al.
|
|
|
|
|
آدرس
|
medicinal bioconvergence research center,seoul national university,seoul, South Korea, medicinal bioconvergence research center,seoul national university,seoul, South Korea, medicinal bioconvergence research center,seoul national university,seoul, South Korea, medicinal bioconvergence research center,seoul national university,seoul, South Korea, medicinal bioconvergence research center,seoul national university,seoul, South Korea, medicinal bioconvergence research center,seoul national university,seoul, South Korea, laboratory of molecular pathology,college of pharmacy,seoul national university,seoul, South Korea, college of veterinary medicine,seoul national university,seoul, South Korea, college of veterinary medicine,seoul national university,seoul, South Korea, college of veterinary medicine,seoul national university,seoul, South Korea, department of pathology,samsung medical center,sungkyunkwan university school of medicine,seoul, South Korea, department of thoracic and cardiovascular surgery,samsung medical center,sungkyunkwan university school of medicine,seoul, South Korea, national cancer center,research institute,goyang, South Korea, national cancer center,research institute,goyang, South Korea, national cancer center,research institute,goyang, South Korea, department of biochemistry,school of medicine,kyungpook national university,daegu, South Korea, department of internal medicine,school of medicine,kyungpook national university,daegu, South Korea, department of pathology and laboratory medicine,roswell cancer park institute,buffalo,ny, United States, department of molecular biology,pusan national university,pusan, South Korea, medicinal bioconvergence research center,seoul national university,seoul,south korea,wcu department of molecular medicine and biopharmaceutical sciences,seoul national university,suwon, South Korea, medicinal bioconvergence research center,seoul national university,seoul,south korea,wcu department of molecular medicine and biopharmaceutical sciences,seoul national university,suwon, South Korea
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|